» Articles » PMID: 12943740

The N-terminal of the Estrogen Receptor (ERalpha) Mediates Transcriptional Cross-talk with the Retinoic Acid Receptor in Human Breast Cancer Cells

Overview
Date 2003 Aug 29
PMID 12943740
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Transcriptional cross-talk exists between the estrogen receptor (ERalpha) and retinoic acid receptor (RAR) pathways in human breast cancer cells. We have previously shown that re-expression of ERalpha in ER-negative cells stimulates the transcriptional and growth inhibitory effects of all-trans-retinoic acid (tRA) by a mechanism that is independent of the ER ligands estradiol and tamoxifen. In this study, we generated cell lines stably expressing ERalpha-deletion mutants to elucidate the mechanism whereby ERalpha modulates RAR transcriptional activity. Using RT-PCR and RNAse protection assays, we observed that expression of ERalpha suppresses basal expression of the RA-responsive gene RARbeta2, while allowing it to be strongly induced by tRA. Repression of basal RARbeta2 transcription was confirmed by transient expression of the reporter plasmid betaRE-tk-CAT, containing the RARbeta2 promoter. In the ERalpha-negative cells, on the other hand, transcription was only weakly induced by RA. We further determined that this effect of ERalpha on RARbeta induction required the N-terminal AF-1-containing region, including the DNA-binding domain, but was independent of the C-terminal ligand-binding domain. Consistent with these results, the ER agonist estradiol and the AF-2 antagonist 4-hydroxytamoxifen had no significant effect on betaRARE activity. Conversely, the full ER antagonist ICI 182,780, which blocks ERalpha AF-1 activity, was able to completely relieve repression of basal betaRARE activity. The effect of ERalpha is specific for RAR-mediated transcription and does not occur on promoters containing typical response elements for the Vitamin D or thyroid hormone receptors. Moreover, the cross-talk between ERalpha and RAR does not seem to be mediated by sequestration of a number of common co-regulators, suggesting a novel mechanism whereby the N-terminal region of ERalpha modulates the transcriptional activity of RAR.

Citing Articles

An R package for generic modular response analysis and its application to estrogen and retinoic acid receptor crosstalk.

Jimenez-Dominguez G, Ravel P, Jalaguier S, Cavailles V, Colinge J Sci Rep. 2021; 11(1):7272.

PMID: 33790340 PMC: 8012374. DOI: 10.1038/s41598-021-86544-0.


From Influenza Virus Infections to Lupus: Synchronous Estrogen Receptor and RNA Polymerase II Binding Within the Immunoglobulin Heavy Chain Locus.

Jones B, Sealy R, Penkert R, Surman S, Birshtein B, Xu B Viral Immunol. 2020; 33(4):307-315.

PMID: 32105583 PMC: 7247044. DOI: 10.1089/vim.2019.0144.


Matters of life and death: How estrogen and estrogen receptor binding to the immunoglobulin heavy chain locus may influence outcomes of infection, allergy, and autoimmune disease.

Jones B, Penkert R, Surman S, Sealy R, Pelletier S, Xu B Cell Immunol. 2019; 346:103996.

PMID: 31703914 PMC: 7368653. DOI: 10.1016/j.cellimm.2019.103996.


Transcriptomic Analysis Shows Decreased Cortical Expression of NR4A1, NR4A2 and RXRB in Schizophrenia and Provides Evidence for Nuclear Receptor Dysregulation.

Corley S, Tsai S, Wilkins M, Weickert C PLoS One. 2016; 11(12):e0166944.

PMID: 27992436 PMC: 5161508. DOI: 10.1371/journal.pone.0166944.


Estradiol-Estrogen Receptor α Mediates the Expression of the CXXC5 Gene through the Estrogen Response Element-Dependent Signaling Pathway.

Yasar P, Ayaz G, Muyan M Sci Rep. 2016; 6:37808.

PMID: 27886276 PMC: 5122896. DOI: 10.1038/srep37808.